Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Mural Oncology Plc ( (MURA) ) is now available.
On June 11, 2025, Mural Oncology Plc held its annual general meeting where shareholders elected six directors to serve until the 2026 meeting. Additionally, shareholders ratified the selection of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2025, and authorized the board to set the auditor’s remuneration.
The most recent analyst rating on (MURA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Mural Oncology Plc stock, see the MURA Stock Forecast page.
Spark’s Take on MURA Stock
According to Spark, TipRanks’ AI Analyst, MURA is a Neutral.
Mural Oncology Plc’s stock is weighed down by its financial challenges, including zero revenue and high cash burn, which significantly impact its overall score. Technical indicators suggest some positive momentum, but the stock faces resistance. Valuation remains unattractive due to unprofitability. However, upcoming clinical milestones and strategic focus on efficiency provide potential upside, reflected in the corporate events score.
To see Spark’s full report on MURA stock, click here.
More about Mural Oncology Plc
Mural Oncology Plc operates in the healthcare industry, focusing on oncology treatments and services. The company is engaged in developing innovative cancer therapies and is committed to advancing cancer care through research and collaboration.
Average Trading Volume: 4,706,906
Technical Sentiment Signal: Strong Sell
Current Market Cap: $44.04M
For a thorough assessment of MURA stock, go to TipRanks’ Stock Analysis page.